24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Diabetes Treatment Failure May Actually Be NonadherenceArtificial Intelligence Can Detect Diabetic RetinopathyMore Than 1 in 10 Patients May Be Overtreated for DiabetesPioglitazone Has Limited Effect in Lipoatrophic DiabetesFracture Risk Higher for Seniors With DiabetesCGM Use in Pregnancy Improves Neonatal OutcomesClosed-Loop Control Benefits T1DM in Prolonged Winter SportHeath Tip: Dining Out If You Have DiabetesExenatide Doesn't Up Cardiovascular Risk in T2DMIncreasing Salt Intake Tied to Diabetes RiskSotagliflozin Linked to Improved Glycemic Control in T1DMGreater Awareness Needed for Potential of T2DM RemissionCan Coffee or Tea Extend Survival With Diabetes?Could Artificial Sweeteners Raise Your Diabetes Risk?Could Swine Flu Be Linked to Type 1 Diabetes?'Upside' to Diabetes Really Isn'tLifestyle Tips for Better Diabetes ControlDiabetes Threatens Kidneys, Vision of Millions of Americans2017 Standards of Medical Care in Diabetes ReleasedBiomarkers Can Predict Rapid Drop in Renal Function in T2DMMany Teens With Type 1 Diabetes Report Disordered EatingCognitive Test Predicts Elderly Insulin Injection SuccessHigher Event Rate of T2DM in Polycystic Ovary SyndromeNovel Genetic Variant in IGF2 Linked to Reduced T2DM RiskFatty Acid Remodeling Seen in T2DM Remission Post Bariatric SxDiacerein Reduces Mean Hemoglobin A1c Levels in T2DMHealth Tip: Risk Factors for PrediabetesTablet Use Encourages Patients to Explore Diabetes RiskOnce-Yearly Counseling Tied to More Physical Activity in T2DMIn T2D, Glycemic Control Up With Continuous Glucose MonitoringSecure Messaging Linked to Better Diabetes ManagementStudies Often Fail to Include Info on T2DM Medication AdherenceIntensive Blood Pressure Tx Aids Those With PrediabetesLifestyle Intervention Only Offers Modest Benefit in Type 2 DiabetesSleep Duration Inversely Linked to Risk Markers of T2DM in KidsCould Big Lifestyle Changes Be Key to Managing Type 2 Diabetes?Variation in Participation in Diabetes Self-Management ClassTeam-Based Online Game May Improve Glycemic Control in T2DArtificial Sweeteners Trick the Brain: StudyCharacteristics of Diabetes in Infancy ExploredImmunotherapy Shown Safe in Type 1 Diabetes Clinical TrialOnline Game Helps Those With Diabetes Control Blood SugarHeart Health Ignored by Many With Type 2 DiabetesMortality Down Only for Gastric Bypass Patients With DiabetesInstagram Shows How Diabetics Really Wear a Glucose MonitorWhat Diabetics Need to Know About Over-the-Counter MedsEngineered Skin Cells Control Type 2 Diabetes in Mice: StudySimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesDiabetes Symptoms Appear to Spread Via Prion-Like MechanismPoor Adherence to Self-Monitoring of Glucose in GDM
Links
Related Topics

Medical Disorders

Increased Use of Newer Meds for Diabetic Nephropathy in the U.S.


HealthDay News
Updated: Mar 27th 2017

new article illustration

MONDAY, March 27, 2017 (HealthDay News) -- From 2010 to 2014 there was an increase in use of diabetes medications, including sulfonylureas and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), among patients with diabetic nephropathy, according to a study published online March 15 in the Journal of Clinical Pharmacy and Therapeutics.

Using the IMS Health's National Disease and Therapeutic Index, Oyintayo Ajiboye, M.D., M.P.H., and Jodi B. Segal, M.D., M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, analyzed medication prescription patterns for six classes of medications among patients with diabetic nephropathy.

The researchers observed an increase in the number of annual office visits, from 772,860 in 2010 to 1,868,618 in 2013, followed by a decrease to 830,596 in 2014. Of the four classes of diabetes medications included in the study, the most frequently used were sulfonylureas and DPP-4 inhibitors. Use of DDP-4 inhibitors gradually increased; by the last quarter of 2014 they were used in 54 percent of treatment visits. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were prescribed in most treatment visits across these years, with peaks above 90 percent, although there were some periods when their use was low.

"Future studies should assess if the utilization of these medications continues to increase over time and should generate more evidence on the factors affecting the different treatment options so that more focused interventions can be done to improve patient outcomes," the authors write.

Abstract
Full Text (subscription or payment may be required)